These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

MASLD (formerly known as non-alcoholic fatty liver ... cirrhosis. These were also compared with 16 age-matched healthy volunteers. Each study participant was equipped with an actigraph -- to track ...

The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough ...

On 3 April 2024, the Company announced publication of the results of the RED DESERT and SAHARA proof-of-concept studies, in the prestigious peer-reviewed journal European Journal of Heart Failure.

Markers of liver injury were significantly improved ... a patient population which is hard to treat and high risk to progress to cirrhosis. We are looking forward to looking more in depth at ...